Orgenesis Financial Statements From 2010 to 2024
ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Check Orgenesis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Orgenesis' main balance sheet or income statement drivers, such as , as well as many indicators such as . Orgenesis financial statements analysis is a perfect complement when working with Orgenesis Valuation or Volatility modules.
Orgenesis |
Orgenesis OTC Stock Return On Equity Analysis
Orgenesis' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Orgenesis Return On Equity | -7.27 |
Most of Orgenesis' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orgenesis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Orgenesis has a Return On Equity of -7.2725. This is 69.66% lower than that of the Biotechnology sector and 80.05% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Orgenesis Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Orgenesis's current stock value. Our valuation model uses many indicators to compare Orgenesis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orgenesis competition to find correlations between indicators driving Orgenesis's intrinsic value. More Info.Orgenesis is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Orgenesis' earnings, one of the primary drivers of an investment's value.About Orgenesis Financial Statements
Orgenesis shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Orgenesis investors may analyze each financial statement separately, they are all interrelated. The changes in Orgenesis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Orgenesis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as various price indices. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Transaction History View history of all your transactions and understand their impact on performance |